Clinical Trials Sponsored by Harbin Institute of Hematology

Total 479 results

Chinese Society of Hematology
Harbin Institute of Hematology & Oncology

Unknown

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

Myelodysplastic Syndrome (MDS)
Harbin Hematology and Oncology Institute

Completed

Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL (BLING)

B-precursor Acute Lymphoblastic Leukemia

China
Institute of Rheumatology, Prague
Karolinska Institutet

Completed

Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM (Prometheus)

Dermatomyositis | Polymyositis

Czech Republic
Institute of Hematology & Blood Diseases Hospital

Recruiting

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

Gene Therapy | Transfusion-dependent Beta-Thalassemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Cyclophosphamide Added to Standard Immunosuppressive Therapy With Eltrombopag as Front-line Therapy in Patients With Severe Aplastic Anemia

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

Polycythemia Vera

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation | Hematological Disease

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Avatrombopag Combined With IST as First-line Treatment for SAA

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia (2022-CM313-ITP)

Immune Thrombocytopenia | Treatment

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Hemophilia B

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Minimal Residual Disease | Bone Marrow Transplant | Ph+ ALL

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Minimal Residual Disease

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly (SAA)

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Acute Myeloid Leukemia | Measurable Disease

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital

Recruiting

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Acute Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

Chronic Lymphocytic Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Completed

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

COVID-19

China
Institute of Hematology & Blood Diseases Hospital

Terminated

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (LODACA)

Refractory Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Completed

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Acute,Leukemia, Lymphoid

China
Institute of Hematology & Blood Diseases Hospital

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

AML

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria (PNH-2012)

Urination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation

COVID-19 | Hematopoietic Stem Cell Transplantation

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Follicular Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia

Aplastic Anemia | Platelet Transfusion Refractoriness

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Hemophilia B
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Transplant-Related Disorder

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Transplant-Related Disorder

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease

aGVHD

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

Hemophilia A

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Lymphoblastic Leukemia, Acute, Childhood | Refractory Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Relapsed Leukemia

China

Clinical Trials Sponsored by Harbin Institute of Hematology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations